EASL Podcasts

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.

Faculty

• Patrizia Burra (Moderator)
• Maria Buti (Faculty)
• Peter Jepsen (Faculty)
• Shira Zelber-Sagi (Faculty)

Related episodes

• EASL Studio S6E1: Do we solve MASLD by treating obesity?
• EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policy
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.

Faculty

• Aleksander Krag (Moderator)
• Aftab Ala (Faculty)
• Pavel Strnad (Faculty)
• Alice Turner (Faculty)

Related episodes

• EASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challenges
• EASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challenges

This episode is scheduled in honour of the Rare Disease Day (29 February).

All EASL Studio Podcasts are available on EASL Campus.

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?

Faculty

• Paolo Angeli (Moderator)
• Guadalupe Garcia-Tsao (Faculty)
• Valérie Paradis (Faculty)
• Thomas Reiberger (Faculty)

Related episodes

• EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approach
• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?

All EASL Studio Podcasts are available on EASL Campus.

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.

Faculty

• Thomas Berg (Moderator)
• Katie Kelley (Faculty)
• Daniela Sia (Faculty)
• Juan Valle (Faculty)

This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

All EASL Studio Podcasts are available on EASL Campus.

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.

Faculty

• Pierre-Emmanuel Rautou (Moderator)
• Virginia Hernández-Gea (Faculty)
• Patrick Kamath (Faculty)
• Wim Laleman (Faculty)

Related episodes:

• EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome

All EASL Studio Podcasts are available on EASL Campus.

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.

Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!

Faculty

• Sven Francque (Moderator)
• Willem Pieter Brouwer (Faculty)
• Cyrielle Caussy (Faculty)
• Dimitris Papamargaritis (Faculty)

This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.

Related episodes:

• EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.

Faculty

• Aleksander Krag (Moderator)
• Thomas Berg (Faculty)
• Ahmed Elsharkawy (Faculty)
• Debbie Shawcross (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.

This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.

Faculty

• Debbie Shawcross (Moderator)
• Christian Labenz (Faculty)
• Steve Rodrigues (Faculty)
• Dominique Thabut (Faculty)

This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme.

Related episode

• EASL Studio S2E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy

All EASL Studio Podcasts are available on EASL Campus.

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.

Faculty

• Tom Lüdde (Moderator)
• Christoph Roderburg (Faculty)
• Anna Saborowski (Faculty)
• Arndt Vogel (Faculty)

This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.

Related episodes

• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

All EASL Studio Podcasts are available on EASL Campus.

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.

Faculty

• Palak Trivedi (Moderator)
• Amanda Ricciuto (Faculty)
• Marianne Samyn (Faculty)
• Christoph Schramm (Faculty)

This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.

Related episodes

• EASL Studio S5E4: PBC: the itch we need to scratch
• EASL Studio from EASL Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023
• EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patients

All EASL Studio Podcasts are available on EASL Campus.

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.

Faculty

• Thomas Reiberger (Moderator)
• Juan Gonzalez-Abraldes (Faculty)
• Elisa Pose (Faculty)
• Jonel Trebicka (Faculty)

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Related episodes

• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
• EASL Studio S4E4: JHEP Live: is the term ‘decompensated cirrhosis’ outdated?
• EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

All EASL Studio Podcasts are available on EASL Campus.

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.

Faculty

• Zobair Younossi (Moderator)
• Laurent Castera (Faculty)
• Camilla Dalby Hansen (Faculty)
• Amalia Gastaldelli (Faculty)

This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).

This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.

Related episodes:

• EASL Studio S3E7: Bugs and the liver — the role of the gut microbiome in liver diseases
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases.

Faculty

• Aleksander Krag (Moderator)
• Juan Pablo Arab (Faculty)
• Alexandre Louvet (Faculty)
• Maru Rinella (Faculty)

Related episodes:

• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S3E5: JHEP Live: Stigma and alcohol

All EASL Studio Podcasts are available on EASL Campus.

Join the faculty as they take a deep dive into hepatitis delta (HDV) to:

• Shed light on the controversies surrounding this disease.
• Share their perspectives on the latest and most hotly debated recommendations.
• Discuss how these new recommendations will shape the future of research and patient care.

Faculty

• Thomas Berg (Moderator)
• Maurizia Brunetto (Faculty)
• Ohad Etzion (Faculty)

Related episodes:

• EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
• EASL Studio S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

All EASL Studio Podcasts are available on EASL Campus.

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life.

This episode was scheduled according to the international calendar for the World Food Day (16 October)

Faculty

• Shira Zelber Sagi (Moderator)
• Riccardo Dalle Grave (Faculty)
• Giulio Marchesini (Faculty)

Related episodes

• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research.

Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than ever.

Faculty

• Anna Saborowski (Moderator)
• Kelly Korreck (Faculty)
• Maria Panagioti (Faculty)
• Dina Tiniakos (Faculty)

Related Nature article by participant Kelly Korreck: How I managed my intense burnout

This episode is scheduled according to the international calendar for the World Mental Health Day (10 October).

All EASL Studio Podcasts are available on EASL Campus.

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article:

• Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?
• What are the main issues regarding the measurement and thresholds for MRFs?
• Is the introduction of the MetALD category clinically justified?
• Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be accounted for in disease classification systems?

Faculty

• Vlad Ratziu (Moderator)
• Giulio Marchesini (Faculty)
• Nancy Reau (Faculty)
• Roberto Vettor (Faculty)

Related article

• A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Related episodes

• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode covers the highlights of the SLD Summit 2023, including:

• Physiopathological mechanism
• Problems encountered in the cirrhotic stage in SLD
• Novelties about liver biopsies

Faculty

• Sven Francque (Moderator)
• Quentin Anstee (Faculty)
• Frank Tacke (Faculty)
• Maja Thiele (Faculty)

Related episodes

• EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
• EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E23: The conundrum of NASH: The growing global disease burden with low disease awareness
• EASL Studio S4E22: JHEP Live: New and promising drugs for NASH on the horizon

All EASL Studio Podcasts are available on EASL Campus.

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide.

2 different settings:

• HEV genotypes 1 and 2 cause primarily in water-born outbreaks inn resource-limited settings
• HEV genotypes 3 and 4 have emerged as porcine zoonoses in middle and high-income areas, including Europe

This Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent highlights as well as current challenges in basic, translational, and clinical research on Hepatitis E.

Learn more about the viral and host determinants for the diverse clinical outcomes of HEV genotype 3 infections, the challenge of chronic Hepatitis E in immunocompromised patients, as well as the current state of vaccine development and other preventive measures.

Faculty

• Darius Moradpour (Moderator)
• Patrick Behrendt (Faculty)
• Montserrat Fraga Christinet (Faculty)
• Eike Steinmann (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Thirty percent of the global population have too much fat in their liver. The big question is: are they really sick when most will not end up with liver disease?
This episode discusses:

• How should they be assessed and by whom?
• What does this mean to healthcare systems?
• Are there downsides to systematic screening?

Faculty

• Aleksander Krag (Moderator)
• Alina Allen (Faculty)
• Manal El-Sayed (Faculty)
• Ian Rowe (Faculty

Related episode

• EASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature

All EASL Studio Podcasts are available on EASL Campus.